Long‐acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population‐based cohort study
Main finding · Incident DRResult — go to the resultHazard ratio 1.04 95% CI 0.99–1.09Authors' conclusion
Compared with NPH insulin, long-acting insulin analogues were not associated with the risk of incident DR among patients with type 2 diabetes. This finding provides important reassurance regarding the safety of long-acting insulin analogues with respect to incident DR.
Study context
- Population
- Patients with T2D initiating long-acting insulin analogue or Neutral Protamine Hagedorn (NPH) insulin, Clinical Practice Research Datalink Aurum
- Participants
- 66,280 vs 66,173
- Exposure
- Long-acting insulin analogues vs NPH insulin
- Insulin analoguesn = 66,280
- NPH insulinn = 66,173reference
- Outcome
- Incident diabetic retinopathy (DR)
Methodological detailspopulation-based, inverse probability of treatment weighting
- Population-based
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
Hazard ratio
1.04
95% CI 0.99–1.09
By group
Insulin analogues
101.7 per 1000 person-years
CI 98.7–104.8
NPH insulin
93.2 per 1000 person-years
CI 90.0–96.5
Insulin analoguesvs NPH insulin
HR 1.04 (95% CI 0.99–1.09)
Observational data: associations, not effects.
Further findings
| Outcome | Adjusted HR (95% CI) | |
|---|---|---|
| Proliferative DR | 0.84 (0.66–1.07) | |
| Non-proliferative DR | 1.02 (0.97–1.08) | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Long‐acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population‐based cohort study. Diabetes Obes Metab. Published 11 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →